PT-141 10mg
- ≥99% purity by HPLC
- Janoshik COA with every lot
- Lot-traceable from synthesis
- EU-synthesised
Specifications
Third Party Lab Tested
Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.
Storage & Handling
Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.
Reconstitution
Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.
Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →Central melanocortin-receptor research.
PT-141, also known as Bremelanotide, is a synthetic cyclic melanocortin peptide derived from the Melanotan 2 research lineage. It is studied primarily through central melanocortin receptors, particularly MC4R, which distinguishes its mechanism from compounds investigated through peripheral vascular pathways.
This 10 MG PT-141 peptide is supplied as a lyophilized research vial alongside other independently analysed NZM-Labs peptides. HPLC purity analysis and mass-spectrometry identity testing are performed for each production lot, with lot-specific documentation available by batch. For laboratory research only.
| Compound | PT-141 (Bremelanotide) |
|---|---|
| Sequence length | 7 amino acids |
| Molecular mass | 1025.2 Da |
| Mechanism / research class | Synthetic melanocortin analogue |
| Example laboratory preparation | 10 MG vial with 2 mL bacteriostatic water (0.9% benzyl alcohol) |
| Calculated concentration | 5 mg per 1.0 mL |
| Supply format | PT-141 · 10 MG lyophilized research vial |
| Storage, lyophilized | store below 16°C for up to 24 months |
| Storage, reconstituted | refrigerate and use within 30 days |
Synthesised.
Verified.
Documented.
Backed by research.
Measured in results.
Each tag opens the cited literature behind that effect. References are linked to PubMed.
PT-141 (Bremelanotide) operates centrally on MC4R rather than peripherally on vascular tissue - the mechanistic distinction from PDE5-inhibitor research compounds. The most-cited centrally-acting reference in arousal-pathway literature.
- Pfaus JG et al. Bremelanotide and CNS arousal pathways. Eur J Pharmacol. 2007;571(1):42-50. PubMed ↗
Reference clinical literature in male erectile-research populations reports response on validated arousal-research scales, distinct from peripheral PDE5-inhibitor mechanism.
- Diamond LE et al. Bremelanotide for erectile dysfunction. J Sex Med. 2006;3(4):628-638. PubMed ↗
Questions?
We have answers.
No reviews yet
Write a review
Share your experience with PT-141 10mg. Reviews are published after a manual check.
